Reading RLYB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RLYB free→Reading RLYB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RLYB free→QuarterlyIQ Insights · RLYB
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Changes in Control of Registrant. To the extent required by this Item, the information included in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. To the extent required by this Item, the information included in
Unregistered Sales of Equity Securities. To the extent required by this Item, the information included in
Entry into a Material Definitive Agreement. Merger Agreement On May 31, 2026, Rallybio Corporation, a Delaware corporation (“ Rallybio ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with Avenzo Therapeutics, Inc., a Delaware corporation (“ Avenzo ”), a clinical-stage biotechnology company developing next-generation oncology therapies, and Farmington Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Rallybio (“ Merger Sub ”)…
Termination of a Material Definitive Agreement. As previously disclosed, on March 1, 2026, Rallybio Corporation (“ Rallybio ”) entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with Candid Therapeutics, Inc. (“ Candid ”), and Farmington Merger Sub, Inc., a wholly-owned subsidiary of Rallybio (“ Merger Sub ”). For a description of the Merger Agreement, please refer to
of Rallybio’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “ SEC ”) on March 2, 2026 (the “ March 2026 8-K ”), which description is incorporated herein by reference. Such description is qualified in its entirety by reference to the full text of the Merger Agreement, which is attached as Exhibit 2.1 to the March 2026 8-K, which is incorporated herein by reference. On May 3, 2026, Candid terminated the Merger Agreement concurrently with entering into a Permi…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 31, 2026, Rallybio Corporation (Rallybio) announced that Steven Ryder, M.D., who has served as Rallybio’s Chief Medical Officer since January 2019, will leave Rallybio effective immediately. In connection with Dr. Ryder’s separation, Rallybio and Dr. Ryder have entered into a separation agreement (the Separation Agreement) pursuant to whic…
Entry into a Material Definitive Agreement. Merger Agreement On March 1, 2026, Rallybio Corporation, a Delaware corporation (“ Rallybio ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with Candid Therapeutics, Inc., a Delaware corporation (“ Candid ”), a clinical-stage biotechnology company advancing a leading portfolio of T-cell engager (TCE) therapeutics for autoimmune diseases, and Farmington Merger Sub, Inc., a Delaware corporation and wholly…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. To the extent required by this Item, the information included in
Unregistered Sales of Equity Securities. To the extent required by this Item, the information included in
Changes in Control of Registrant. To the extent required by this Item, the information included in
of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed by Rallybio Corporation (“the Company”), on February 24, 2025, the Company received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department notifying the Company that the closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the prior 30 consecutive business…
of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Completion of Acquisition or Disposition of Assets. The information set forth in
Entry into a Material Definitive Agreement. On July 8, 2025, Rallybio Corporation (“Rallybio”) entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Recursion Pharmaceuticals, Inc., (“Recursion”), Exscientia Ventures I, Inc., an indirect wholly-owned subsidiary of Recursion (“Buyer”) and Rallybio IPB, LLC, a wholly-owned subsidiary of Rallybio (“Seller”), pursuant to which Buyer purchased 50% of the issued and outstanding membership interests (the “Membership I…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 25, 2025, Rallybio Corporation (Rallybio) entered into an employment agreement (the Employment Agreement) with Steven Ryder, M.D., Rallybio’s Chief Medical Officer. Dr. Ryder has served as Rallybio’s Chief Medical Officer since January 2019. Pursuant to the Employment Agreement, Dr. Ryder will receive an initial annual base salary of $531,2…
of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Other Events. On March 13, 2025, Rallybio Corporation (the “Company”) and TD Securities (USA) LLC (“TD Cowen”) entered into Amendment No. 1 (the “Amendment”) to the Sales Agreement dated August 8, 2022 (as amended, the “Sales Agreement”), which Amendment reduced the amount of the Company’s common stock, par value $0.0001 per share (the “Shares”), that can be sold by the Company under the Sales Agreement, from an aggregate offering price of up to $100,000,000 to an aggregate offering price of…
of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 24, 2025, Rallybio Corporation (the “Company” or “Rallybio”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the last 30 consecutive business days (the “N…
Importance-ranked changes since the prior daily snapshot.
Signal changed from 'mixed' to 'cautious'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.